• Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Journal of Austrian Chemistry

Journal for the Chemical Industry in Austria

Hidradenitis

Dr. Gottlieb to present XBiotech’s research on Hidradenitis

2019-02-01 by Florian Fischer

XBiotech announced today that Dr. Alice Gottlieb, M.D., Ph.D., will be giving the presentation “Bermekimab Shows Efficacy for Treating Hidradenitis Suppurativa (HS), Including Marked Reduction in Pain” during the afternoon session on March 2nd, 2019 at the American Aacademy of Dermatology annual meeting being held at the Walter E. Washington Convention Center in Washington, D.C.  The presentation, which was accepted as “late-breaking research: clinical trials,” will provide details of the Company’s recent Phase II clinical trial results in 42 HS patients that received 400mg subcutaneous weekly doses of bermekimab in a 12-week treatment regimen.

The study involved two treatment groups of subjects: those who had failed prior anti-TNF therapy (n=24); and those with no prior anti-TNF treatment history (n=18). 

The study’s Chair, Dr. Alice Gottlieb, M.D., Ph.D., Clinical  Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY, commented, “I am looking forward to presenting these very exciting results for a new drug that can help address a significant unmet need for patients suffering from hidradenitis suppurativa.”

A major finding in the study was a significant treatment-related reduction of pain in the HS patients. Pain is widely recognized among experts as a key objective for HS treatment, but this symptom has been largely unaddressed by available approved therapies. No approved monotherapy for HS has shown a significant effect on pain1.

Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disorder affecting areas rich in apocrine glands. Nodules appear in the affected areas and progressively become swollen with spontaneous rupture and release of pus. This process occurs repeatedly leading to formation of deep sinus tracts and painful dermal abscesses. Pain is a paramount condition in patients suffering from HS, as this chronic inflammation and accompanying pain account for the fact that HS is ranked first among skin disorders in terms of adversely affecting quality of life. The global prevalence for HS is estimated at up to 4% of the population.

Header Photo Credit: Dermatology World

Filed Under: News Tagged With: biotech, Hidradenitis, International

Primary Sidebar

Recent Posts

  • Academies of sciences and German Research Foundation call for new European genetic engineering legislation
  • COMPAMED 2019 finishes with success
  • Austrian B&R mourns death of company founder
  • Open letter by European and UK Chemical Industry Organisations
  • Endress+Hauser shows Growth in 2018

Archives

  • December 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Case Study
  • Fairs
  • Finance
  • News
  • Products
  • Publication

Footer

The WelkinMedia House

  • Chemie Zeitschrift
  • Kunststoffzeitschrift
  • labor
  • L&B

Recent Posts

  • Academies of sciences and German Research Foundation call for new European genetic engineering legislation
  • COMPAMED 2019 finishes with success
  • Austrian B&R mourns death of company founder
  • Open letter by European and UK Chemical Industry Organisations
  • Endress+Hauser shows Growth in 2018

Tags

AGRANA Austria Automation Awards BIOFACH biology biotech Brexit Chemical Industry Organisations Clariant commercial laundry COMPAMED data mining Death notice ECP Endress+Hauser Evonik Extraction Fairs Finance Healthcare HHU Hidradenitis industry 4.0 International ISO Standards laboratory instrumentation LAUDA mycon NetComposites NOP-1 OPTIMA OPTIMA OSR Packaging pharma photovoltaic polymers sugar sulphur Syrris TEKA Tissue World TU Munich VAC-Cubes Water Science

Copyright © 2023 · Metro Pro On Genesis Framework · WordPress · Log in